

Cover Story
Free
By Matthew Bin Han Ong
Update: The New England Journal of Medicine's subsequent response after this article is published is appended at the end.
In Brief


Drugs & Targets
Trending Stories
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- Cancer centers adapt to life without site visits as NIH changes CCSG review
- GRAIL to use new study results to seek FDA approval of Galleri MCD test
- Jonathan Licht named president, chief scientific officer at Van Andel Institute
- Friends publishes three white papers ahead of annual meeting
Topics: Clinical trials on rare cancers, combination drug trials, multi-regional studies - Duke brain cancer researcher Kyle Walsh named director of NIEHS











